{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T03:45:45Z","timestamp":1770349545395,"version":"3.49.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004085","name":"Ministry of Education, Science and Technology","doi-asserted-by":"publisher","award":["2018R1A6A1A03023718"],"award-info":[{"award-number":["2018R1A6A1A03023718"]}],"id":[{"id":"10.13039\/501100004085","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004085","name":"Ministry of Education, Science and Technology","doi-asserted-by":"publisher","award":["2019H1A2A1076925"],"award-info":[{"award-number":["2019H1A2A1076925"]}],"id":[{"id":"10.13039\/501100004085","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004085","name":"Ministry of Education, Science and Technology","doi-asserted-by":"publisher","award":["2019R1A2C1008619"],"award-info":[{"award-number":["2019R1A2C1008619"]}],"id":[{"id":"10.13039\/501100004085","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.leukres.2020.106398","type":"journal-article","created":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T02:02:42Z","timestamp":1591063362000},"page":"106398","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["A452, HDAC6-selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in IMiDs-resistant multiple myeloma"],"prefix":"10.1016","volume":"95","author":[{"given":"Go Woon","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye-Rim","family":"Won","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo-Keun","family":"Yeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Woo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu Hyun","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3753-4415","authenticated-orcid":false,"given":"So Hee","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.leukres.2020.106398_bib0005","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nrc2189","article-title":"Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets","volume":"7","author":"Hideshima","year":"2007","journal-title":"Nat. Rev. Cancer"},{"issue":"11","key":"10.1016\/j.leukres.2020.106398_bib0010","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.leukres.2020.106398_bib0015","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/leu.2009.236","article-title":"Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma","volume":"24","author":"Quach","year":"2010","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.leukres.2020.106398_bib0020","first-page":"499","article-title":"HDAC6selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in multiple myeloma","volume":"55","author":"Won","year":"2019","journal-title":"Int. J. Oncol."},{"issue":"1","key":"10.1016\/j.leukres.2020.106398_bib0025","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.mayocp.2015.11.007","article-title":"Multiple myeloma: diagnosis and treatment","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Mayo Clin. Proc."},{"issue":"11","key":"10.1016\/j.leukres.2020.106398_bib0030","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/leu.2012.119","article-title":"Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide","volume":"26","author":"Lopez-Girona","year":"2012","journal-title":"Leukemia"},{"issue":"6168","key":"10.1016\/j.leukres.2020.106398_bib0035","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"issue":"18","key":"10.1016\/j.leukres.2020.106398_bib0040","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","article-title":"Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide","volume":"118","author":"Zhu","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2020.106398_bib0045","doi-asserted-by":"crossref","first-page":"232546","DOI":"10.1155\/2014\/232546","article-title":"Implications of heterogeneity in multiple myeloma","volume":"2014","author":"de Mel","year":"2014","journal-title":"Biomed Res. Int."},{"issue":"3","key":"10.1016\/j.leukres.2020.106398_bib0050","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3390\/cells1030558","article-title":"Autophagy and transporter-based multi-drug resistance","volume":"1","author":"Kumar","year":"2012","journal-title":"Cells"},{"issue":"9","key":"10.1016\/j.leukres.2020.106398_bib0055","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1182\/blood-2016-02-698092","article-title":"Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes","volume":"128","author":"Kortum","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2020.106398_bib0060","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41408-019-0173-0","article-title":"Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4","volume":"9","author":"Zhu","year":"2019","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.leukres.2020.106398_bib0065","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","article-title":"Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy","volume":"25","author":"Lohr","year":"2014","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.leukres.2020.106398_bib0070","doi-asserted-by":"crossref","DOI":"10.3390\/cells8111432","article-title":"Biological background of resistance to current standards of care in multiple myeloma","volume":"8","author":"Mogollon","year":"2019","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.leukres.2020.106398_bib0075","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nrclinonc.2014.216","article-title":"Multiple myeloma and chronic leukaemias in 2014: improved understanding of disease biology and treatment","volume":"12","author":"San-Miguel","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.leukres.2020.106398_bib0080","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1053\/j.seminoncol.2013.07.007","article-title":"Novel agents for multiple myeloma to overcome resistance in phase III clinical trials","volume":"40","author":"Orlowski","year":"2013","journal-title":"Semin. Oncol."},{"issue":"11","key":"10.1016\/j.leukres.2020.106398_bib0085","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","article-title":"Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial","volume":"15","author":"San-Miguel","year":"2014","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.leukres.2020.106398_bib0090","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1634\/theoncologist.2017-0301","article-title":"EMA review of Panobinostat (Farydak) for the treatment of adult patients with relapsed and\/or refractory multiple myeloma","volume":"23","author":"Tzogani","year":"2018","journal-title":"Oncologist"},{"issue":"24","key":"10.1016\/j.leukres.2020.106398_bib0095","doi-asserted-by":"crossref","first-page":"8567","DOI":"10.1073\/pnas.0503221102","article-title":"Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma","volume":"102","author":"Hideshima","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"11","key":"10.1016\/j.leukres.2020.106398_bib0100","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1182\/blood-2011-10-387365","article-title":"Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma","volume":"119","author":"Santo","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2020.106398_bib0105","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/carcin\/bgx121","article-title":"A potent hydroxamic acid-based, small-molecule inhibitor A452 preferentially inhibits HDAC6 activity and induces cytotoxicity toward cancer cells irrespective of p53 status","volume":"39","author":"Ryu","year":"2018","journal-title":"Carcinogenesis"},{"issue":"6","key":"10.1016\/j.leukres.2020.106398_bib0110","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1002\/mc.22983","article-title":"The HDAC6-selective inhibitor is effective against non-Hodgkin lymphoma and synergizes with ibrutinib in follicular lymphoma","volume":"58","author":"Lee","year":"2019","journal-title":"Mol. Carcinog."},{"issue":"4","key":"10.1016\/j.leukres.2020.106398_bib0115","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.bmcl.2010.12.079","article-title":"Structure and property based design, synthesis and biological evaluation of gamma-lactam based HDAC inhibitors","volume":"21","author":"Choi","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"2","key":"10.1016\/j.leukres.2020.106398_bib0120","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.leukres.2020.106398_bib0125","doi-asserted-by":"crossref","first-page":"e312","DOI":"10.1038\/bcj.2015.38","article-title":"Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma","volume":"5","author":"Hideshima","year":"2015","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2020.106398_bib0130","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3389\/fonc.2019.00249","article-title":"MPT0G413, a novel HDAC6-selective inhibitor, and bortezomib synergistically exert anti-tumor activity in multiple myeloma cells","volume":"9","author":"Huang","year":"2019","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.leukres.2020.106398_bib0135","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/leu.2017.322","article-title":"Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma","volume":"32","author":"Ray","year":"2018","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.leukres.2020.106398_bib0140","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20181916","article-title":"The selective HDAC6 inhibitor Nexturastat A induces apoptosis, overcomes drug resistance and inhibits tumor growth in multiple myeloma","volume":"39","author":"Sun","year":"2019","journal-title":"Biosci. Rep."},{"issue":"5","key":"10.1016\/j.leukres.2020.106398_bib0145","doi-asserted-by":"crossref","first-page":"274","DOI":"10.5483\/BMBRep.2014.47.5.134","article-title":"Establishment and characterization of bortezomib-resistant U266 cell line: constitutive activation of NF-\u03baB-mediated cell signals and\/or alterations of ubiquitylation-related genes reduce bortezomib-induced apoptosis","volume":"47","author":"Park","year":"2014","journal-title":"BMB Rep."},{"key":"10.1016\/j.leukres.2020.106398_bib0150","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/bjh.12622","article-title":"Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity","volume":"164","author":"Gandhi","year":"2014","journal-title":"BJH"},{"issue":"6","key":"10.1016\/j.leukres.2020.106398_bib0155","first-page":"1681","article-title":"Mechanisms of glucocorticoid-mediated apoptosis in hematological malignancies","volume":"8","author":"Greenstein","year":"2002","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.leukres.2020.106398_bib0160","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.3324\/haematol.2017.186601","article-title":"Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients","volume":"103","author":"Franssen","year":"2018","journal-title":"Haematologica"},{"issue":"68","key":"10.1016\/j.leukres.2020.106398_bib0165","doi-asserted-by":"crossref","first-page":"112917","DOI":"10.18632\/oncotarget.22872","article-title":"Role of IRF4 in resistance to immunomodulatory (IMid) compounds((R)) in Waldenstrom\u2019s macroglobulinemia","volume":"8","author":"Bertrand","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.leukres.2020.106398_bib0170","article-title":"IKZF1\/3 and CRL4-CRBN E3 ubiquitin ligase mutations and IMiD resistance in multiple myeloma","author":"Barrio","year":"2019","journal-title":"Haematologica"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521262030103X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521262030103X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:00:08Z","timestamp":1758934808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521262030103X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":34,"alternative-id":["S014521262030103X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2020.106398","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A452, HDAC6-selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in IMiDs-resistant multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2020.106398","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106398"}}